MALM, also known as 4-allyloxy-2,5-dimethoxyamphetamine, is a serotonin receptor modulator of the phenethylamine, amphetamine, and DOx families. It is a derivative of the DOx psychedelics TMA-2 and MEM in which the 4-position substituent has been extended. The drug is also the ñ-methyl or amphetamine analogue of 2C-O-16.
The properties and effects of MALM in humans do not appear to be known.
MALM acts as a potent agonist of the serotonin 5-HT<sub>2</sub> receptors. Its affinities (K<sub>i</sub>) were 150nM for the serotonin 5-HT<sub>2A</sub> receptor and 900nM for the serotonin 5-HT<sub>2C</sub> receptor, whereas its activational potencies ( ()) were 2.9nM (89%) at the serotonin 5-HT<sub>2A</sub> receptor and 9.5nM (101%) at the serotonin 5-HT<sub>2B</sub> receptor. Besides the serotonin 5-HT<sub>2</sub> receptors, the drug showed little to no activity at various other assessed targets, such as the monoamine transporters. It does not appear to have been tested for psychedelic-like activity in animals.
MALM was first described in the scientific literature by Daniel Trachsel in 2013. Subsequently, it was characterized in more detail by a group including Trachsel and Matthias Liechti in 2019. The compound's name is said to derive from its benzene ring substituents, "methoxy allyloxy methoxy".
MALM is a controlled substance in Canada under phenethylamine blanket-ban language.